Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company, has announced it will report its Q2 2024 financial results on Thursday, August 8, 2024, after market close. The company will host a public L(earnings) Call at 5:00 pm ET / 3:00 pm MT on the same day. This event will be live-streamed on Recursion's social media platforms, including X (formerly Twitter), LinkedIn, and YouTube. The call is free and open to the public, with an opportunity for attendees to submit questions. Recursion, known for its work in decoding biology to industrialize drug discovery, encourages participation from those interested in asking questions about the company's business developments.
Recursion (NASDAQ: RXRX), un'importante azienda biologica tecnologica in fase clinica, ha annunciato che riporterà i suoi risultati finanziari del Q2 2024 giovedì 8 agosto 2024, dopo la chiusura del mercato. L'azienda ospiterà una chiamata pubblica sugli utili alle 17:00 ET / 15:00 MT lo stesso giorno. Questo evento sarà trasmesso in diretta sulle piattaforme social di Recursion, inclusi X (ex Twitter), LinkedIn e YouTube. La chiamata è gratuita e aperta al pubblico, con un'opportunità per i partecipanti di inviare domande. Recursion, nota per il suo lavoro nel decodificare la biologia per industrializzare la scoperta di farmaci, incoraggia la partecipazione di coloro che sono interessati a porre domande sugli sviluppi aziendali dell'azienda.
Recursion (NASDAQ: RXRX), una destacada empresa de TechBio en etapa clínica, ha anunciado que informará sobre sus resultados financieros del Q2 2024 el jueves 8 de agosto de 2024, después del cierre del mercado. La empresa llevará a cabo una llamada pública de ganancias a las 5:00 pm ET / 3:00 pm MT el mismo día. Este evento se transmitirá en vivo en las plataformas de redes sociales de Recursion, incluyendo X (anteriormente Twitter), LinkedIn y YouTube. La llamada es gratuita y abierta al público, con la oportunidad de que los asistentes envíen preguntas. Recursion, conocida por su trabajo en la decodificación de la biología para industrializar el descubrimiento de medicamentos, fomenta la participación de quienes estén interesados en hacer preguntas sobre los desarrollos comerciales de la empresa.
Recursion (NASDAQ: RXRX)는 주요 임상 단계의 TechBio 회사로서 2024년 2분기 재무 결과를 2024년 8월 8일 목요일, 시장 마감 후 발표할 것이라고 발표했습니다. 회사는 같은 날 오후 5시 ET / 오후 3시 MT에 공식 실적 발표 전화를 진행합니다. 이 이벤트는 Recursion의 소셜 미디어 플랫폼, X(이전 Twitter), LinkedIn, YouTube에서 생중계됩니다. 전화 회의는 무료로 공개되며, 참석자들이 질문을 제출할 수 있는 기회가 있습니다. Recursion은 의약품 발견을 산업화하기 위해 생물학을 해독하는 작업으로 알려져 있으며, 회사의 사업 개발에 관한 질문을 하고 싶은 분들의 참여를 권장합니다.
Recursion (NASDAQ: RXRX), une entreprise TechBio de premier plan en phase clinique, a annoncé qu'elle dévoilerait ses résultats financiers du T2 2024 le jeudi 8 août 2024, après la clôture du marché. L'entreprise tiendra une conférence téléphonique publique sur les résultats à 17h00 ET / 15h00 MT le même jour. Cet événement sera diffusé en direct sur les plateformes de médias sociaux de Recursion, y compris X (anciennement Twitter), LinkedIn et YouTube. L'appel est gratuit et ouvert au public, offrant aux participants la possibilité de poser des questions. Recursion, connue pour son travail de décodage de la biologie afin d'industrialiser la découverte de médicaments, encourage la participation de ceux qui souhaitent poser des questions sur les développements commerciaux de l'entreprise.
Recursion (NASDAQ: RXRX), ein führendes Unternehmen im Bereich TechBio in der klinischen Phase, hat angekündigt, dass es am Donnerstag, den 8. August 2024, nach Börsenschluss seine Finanzergebnisse für das Q2 2024 bekannt geben wird. Das Unternehmen wird am selben Tag um 17:00 Uhr ET / 15:00 Uhr MT eine öffentliche Ergebniskonferenz abhalten. Diese Veranstaltung wird live auf den sozialen Medien von Recursion, einschließlich X (ehemals Twitter), LinkedIn und YouTube, gestreamt. Die Telefonkonferenz ist kostenlos und öffentlich zugänglich, wobei Teilnehmer die Möglichkeit haben, Fragen einzureichen. Recursion, bekannt für seine Arbeit bei der Entschlüsselung der Biologie zur Industrialisierung der Arzneimittelentdeckung, ermutigt die Teilnahme von Interessierten, die Fragen zu den Unternehmensentwicklungen stellen möchten.
- Transparency in financial reporting
- Public engagement through open L(earnings) Call
- Multi-platform accessibility for investors and public
- None.
Company to host public L(earnings) call on August 8th at 5:00 pm ET / 3:00 pm MT
Salt Lake City, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide business updates and report its Q2 2024 financial results on Thursday, August 8, 2024, following the close of the financial markets.
Recursion will host a L(earnings) Call on August 8, 2024 at 5:00 pm Eastern Time / 3:00 pm Mountain Time, interacting with a broad public audience around notable business developments and offering opportunities to ask questions. Recursion will broadcast the live stream from Recursion’s X (formerly Twitter), LinkedIn and YouTube accounts. This event is free, open to the public and encouraged, especially for those wishing to ask questions. Questions can be submitted at https://forms.gle/1LNMHJyWwUuH9sqJ8.
About Recursion
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.
Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal, London, and the San Francisco Bay Area. Learn more at www.Recursion.com, or connect on X (formerly Twitter) and LinkedIn.
Forward-Looking Statements
This document contains information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding early and late stage discovery, preclinical, and clinical programs; licenses and collaborations; prospective products and their potential future indications and market opportunities; Recursion OS and other technologies; business and financial plans and performance; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Report on Form 10-Q. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.
Media Contact
Media@Recursion.com
Investor Contact
Investor@Recursion.com
FAQ
When will Recursion (RXRX) report its Q2 2024 financial results?
What time is Recursion's (RXRX) Q2 2024 L(earnings) Call scheduled for?
How can investors participate in Recursion's (RXRX) Q2 2024 L(earnings) Call?
Can the public ask questions during Recursion's (RXRX) Q2 2024 L(earnings) Call?
